¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer (Q39324549)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer (English)

1 reference

Europe PubMed Central

11 September 2017

1 reference

based on heuristic

inferred from title

Raymond M Reilly

7

object named as

Raymond M Reilly

1 reference

Europe PubMed Central

11 September 2017

author name string

Aisha Fasih

1

1 reference

Europe PubMed Central

11 September 2017

Humphrey Fonge

2

1 reference

Europe PubMed Central

11 September 2017

Zhongli Cai

3

1 reference

Europe PubMed Central

11 September 2017

Jeffrey V Leyton

4

1 reference

Europe PubMed Central

11 September 2017

Ilia Tikhomirov

5

1 reference

Europe PubMed Central

11 September 2017

Susan J Done

6

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

27 June 2012

1 reference

Europe PubMed Central

11 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

11 September 2017

135

1 reference

Europe PubMed Central

11 September 2017

1

1 reference

Europe PubMed Central

11 September 2017

189-200

1 reference

Europe PubMed Central

11 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-012-2137-y

0 references

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Clinical trials of Herceptin(trastuzumab).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Mechanisms of resistance to HER family targeting antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Characterization of a novel tripartite nuclear localization sequence in the EGFR family.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

The pharmacokinetics of cell-penetrating peptides

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2137-Y

21 January 2018

Identifiers

10.1007/S10549-012-2137-Y

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39324549&oldid=1820060393"